When was MSK Pharma founded?

MSK Pharma was founded in 2009.

Where is MSK Pharma located?

MSK Pharma is headquartered in San Diego, United States.

Who is the current CEO of MSK Pharma?

Geraldine Kuo of MSK Pharma. They have also founded 1 company.

How many employees does MSK Pharma have?

As of Jul 01, 2024, the latest employee count at MSK Pharma is 1 - 10.

Is MSK Pharma a funded company?

MSK Pharma is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does MSK Pharma rank among its competitors?

MSK Pharma ranks 577th amongst 2145 active competitors, of which 494 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Life Biosciences, which secured $80M in Apr, 2026.

Who are the top competitors of MSK Pharma?

MSK Pharma's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences. Among them, Life Biosciences secured the most recent funding round in April, 2026.

MSK Pharma - 2026 Company Profile, Team & Competitors

MSK Pharma is an unfunded company based in San Diego (United States), founded in 2009 by Geraldine Kuo. It operates as a Developing drugs to enhance lives and improve well-being. MSK Pharma has not raised any funding yet. The company has 2145 active competitors, including 494 funded and 379 that have exited. Its top competitors include companies like Sutro Biopharma, Synthego and Avidity Biosciences.

Company Details

Developing drugs to enhance lives and improve well-being. The company focuses on creating medications to address critical needs, such as life-threatening allergic reactions and painful injuries. They dedicate significant resources to developing a select number of pharmaceutical products, aiming to make a positive impact on individuals' health and overall quality of life. Their work reflects a commitment to improving patient outcomes and contributing to the advancement of healthcare solutions. They are dedicated to enhancing the lives of everyone they interact with through pharmaceutical innovation.

Key Metrics

Founded Year

2009

Location

San Diego, United States

Stage

Unfunded

Ranked

577^th among 2145 active competitors

Employee Count

1 - 10 as on Jul 01, 2024

Similar Companies

Sutro Biopharma & 2885 more

View MSK Pharma's full profile

MSK Pharma has not raised any funding rounds yet.

The founders of MSK Pharma is Geraldine Kuo. Geraldine Kuo is the CEO of MSK Pharma.

Here are the details of MSK Pharma's key team members:

Geraldine Kuo: Co-Founder & CEO of MSK Pharma.
Contact Info: 1 email address

View details of MSK Pharma's Founder profiles and Board Members

MSK Pharma's employee count trend

MSK Pharma has 1 - 10 employees as of Jul 24. Here is MSK Pharma's employee count trend over the years:

Uncover MSK Pharma's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of MSK Pharma include Sutro Biopharma, Synthego and Avidity Biosciences. Here is the list of Top 10 competitors of MSK Pharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
2nd	Synthego 2012, Redwood City (United States), Acquired	Developer of CRISPR-engineered cell and gene therapies	$460M	8VC, RA Capital Management & 30 others	71/100
3rd	Avidity Biosciences 2012, San Diego (United States), Acquired	RNA therapeutics innovator targeting muscle and other diseases with AOC platform	$143M	RTW Investments, Takeda Ventures & 20 others	70/100
4th	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	67/100
5th	Transcenta 2019, Suzhou (China), Public	Developer of antibody-based therapeutics	$205M	Lilly Asia Ventures, Temasek & 11 others	66/100
6th	Akeso 2012, Zhongshan (China), Public	Developer of antibody drug conjugates for the treatment of broad spectrum diseases	$195M	Orbimed, Sino Biopharmaceutical & 18 others	65/100
7th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases	$4M	Fidelity Investments, Invus & 14 others	64/100
8th	Life Biosciences 2017, Boston (United States), Series D	Biotechnology pioneering cellular rejuvenation therapies to reverse and prevent aging diseases	$261M	Alpha Wave Global, Globalive Capital & 12 others	64/100
9th	Fermentalg 2005, Libourne (France), Public	Innovating with algae for sustainable solutions in nutrition and environmental impact	$30.3M	Demeter, Smalt Capital & 12 others	63/100
10th	Microban 1994, Huntersville (United States), Acquired	Antimicrobial and odor control technologies for durable product protection and freshness	$64.6M	UBS, Brown Brothers Harriman & 1 others	63/100
577th	MSK Pharma 2009, San Diego (United States), Unfunded	Developing drugs to enhance lives and improve well-being	-	-	33/100